Peter Salgo, MD, and Ira M. Klein, MD, MBA, FACP, discuss the treatment of prostate cancer with androgen deprivation therapy (ADT) and note that additional research is necessary to help determine which patient populations are at highest risk for developing resistance following ADT.
Dr Klein explains that after a patient receives ADT, the only indicator that providers have for detecting resistance is disease progression. Unfortunately, he adds, each patient responds differently and the time to onset of resistance is variable.
For this reason, Dr Klein emphasizes the need for additional population-based clinical studies and research on the activation of signaling pathways. Being able to categorize patients, look at specific cell surface markers, and conduct additional next-generation sequencing can help providers appropriately manage their patients, he remarks.
Watch our related Peer Exchange, Oncology Stakeholder Summit 2014: Evidence-Based Decisions to Improve Quality and Regulate Costs
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More